Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
This trial is active, not recruiting.
|Conditions||hyperglucagonemia, hyperglycemia, diabetes mellitus|
|Treatments||oral glucose tolerance test, isoglycemic iv glucose infusion|
|Sponsor||University Hospital, Gentofte, Copenhagen|
|Start date||June 2008|
|End date||March 2009|
|Trial size||20 participants|
|Trial identifier||NCT00704795, H-D-2008-037|
In order to evaluate the potential role of the gastrointestinal (GI) tract in the postprandial hyperglucagonemia, which characterizes type 1 diabetes mellitus (T1DM) (as well as type 2 diabetes mellitus (T2DM)), we wish to investigate the secretion of glucagon in patients with T1DM without residual beta-cell function during 50-g oral glucose tolerance test (OGTT) and during isoglycemic iv glucose infusion. By evaluating C-peptide negative patients with T1DM we aim to describe the glucagon response to glucose (+/-stimulation of the GI tract) independently of the potentially very important regulation of glucagon secretion by endogenous insulin secretion. A more detailed understanding of the inappropriate glucagon secretion in T1DM is highly needed in order to establish new intervention strategies in the future treatment of the growing numbers of T1DM patients.
|Observational model||case control|
Glucagon responses (as assessed by area under curve (AUC)) during 50-g oral glucose tolerance test (OGTT) and isoglycemic iv glucose infusion, respectively.
time frame: months
Responses of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) and glucose-dependent insulinotropic polypeptide (GIP) as assessed by AUC during 50-g OGTT and isoglycemic iv glucose infusion, respectively.
time frame: months
GI-mediated glucose tolerance as assessed by the amount of glucose ingested as compared to the amount of glucose needed to mimic the OGTT curve during the iv glucose infusion.
time frame: Months
Male or female participants from 18 years up to 60 years old.
- Caucasian over 18 years with T1DM (diagnosed according to WHO's criteria) treated with long-acting insulin
- No residual beta-cell function (arginine test without increment in plasma C-peptide - see below)
- BMI <30 kg/m2
- Normal haemoglobin
- Informed consent
- Residual beta-cell function (increment in plasma C-peptide during arginine test - see below)
- Known liver disease or affected liver enzymes (ALAT/ASAT > 2 x upper normal limit)
- Diabetic nephropathy (se-creatinin > 130 µM and/or albuminuria)
- Proliferative diabetic retinopathy (anamnestic)
- Treatment with medication that cannot be discontinued for 14 hours
|Official title||Glucagon Responses Following Oral Glucose and Isoglycemic iv Glucose in Patients With Type 1 Diabetes - a Role for the Gastrointestinal Tract in Diabetic Hyperglucagonemia?|
|Principal investigator||Filip K Knop, MD PhD|
Call for more information